autologous pro-regenerative cells (APRC-CM)—including hematopoietic progenitors, mesenchymal progenitors, endothelial progenitors, and supportive immune cells—have demonstrated potent regenerative, anti-inflammatory, and senolytic properties (; ). APRC-CM contains a rich mixture of extracellular vesicles, cytokines, growth factors, anti-inflammatory mediators, and microRNAs, collectively capable of modulating intercellular signaling, enhancing tissue repair, reducing chronic inflammation, and mitigating cellular senescence (; ). Specifically, using autologous pro-regenerative cell-derived conditioned media confers additional clinical advantages by reducing risks of immune rejection, improving biocompatibility, and circumventing the regulatory and safety challenges typically associated with allogeneic or cell-based therapies (; ; ).
Building on these advances, we conducted a pilot study of a multi-modal intervention combining lifestyle optimisation and targeted supplementation with APRC-CM as an autologous regenerative signalling component. In our study, APRC-CM refers specifically to the conditioned media obtained from a selected subpopulation of autologous peripheral blood mononuclear cells (PBMCs), including hematopoietic and immune progenitors, but not mesenchymal stromal cells, which were not isolated or cultured in our protocol. The primary objective was to assess the safety and tolerability of the protocol through standard clinical biomarkers. Secondary objectives included evaluating the intervention’s preliminary efficacy in modulating biological aging, as measured by validated epigenetic and phenotypic clocks.